Vijaya Diagnostics Q2 Results Review - All Round Beat Builds Ground For Optimism: Yes Securities

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Yes Securities Report.Base business growth in Vijaya Diagnostic Ltd. is running healthy coupled with robust addition from new hubs opened between FY21-23. We had been circumspect about base business expansion, but it does appear to be running at 8-10% YoY in our view and indeed Vijaya has surprised for two quarters in a row. Company has not added any hubs between Jan-Nov-24 barring one opened in Ongole, AP as management focused on integration of PH. With ~4 hubs likely to be opened till Q1 FY26, we believe growth would continue to appear healthy in H2 FY26 and FY27. Accordingly, we have factored 19% YoY rise in footfalls in FY27. Meanwhile, lack of hub addition for most of CY24 may lead to a period where contribution from new hubs might go down and existing centres could be the dominant driver of growth. We marginally tweak FY26 estimate and introduce FY27 forecast. Roll over to FY27 EPS and rise target multiple to ~50 times, at a premium to Dr. Lal and Metropolis given the superior volume growth outlook. Upgrade to Add with revised target price Rs 1,240 (earlier Rs 800). Slowdown in Hyderabad and related core market would be a key risk to our volume assumptions..Click on the attachment to read the full report:.LIC Q2 Results Review - RoEV Improves Due To Underlying Factors, Upgrade To 'Buy': Yes Securities.DISCLAIMERThis report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Vijaya Diagnostics Q2 Results Review - All Round Beat Builds Ground For Optimism: Yes Securities

The brokerage upgrade the stock to 'Add' with revised target price Rs 1,240.

NDTV Profit

NDTV Profit

Follow Us

DOWNLOAD THE APP

Vijaya Diagnostics Q2 Results Review - All Round Beat Builds Ground For Optimism: Yes Securities

The brokerage upgrade the stock to 'Add' with revised target price Rs 1,240.

Choose a plan

Follow Us

DOWNLOAD THE APP